ALIGOS THERAPEUTICS INC

ALIGOS THERAPEUTICS INC (ALGS)

$1.1

-0.02

(-1.79%)

Live

Insights on ALIGOS THERAPEUTICS INC

  • Decreasing Revenue

    Revenue is down for the last 3 quarters, 4.10M → 140.0K (in $), with an average decrease of 55.0% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 3 quarters, -18.62M → -22.95M (in $), with an average decrease of 11.2% per quarter

  • Vs SGEN

    In the last 1 year, Seagen Inc has given 36.8% return, outperforming this stock by 47.2%

Performance

  • $1.09
    $1.12
    $1.10
    downward going graph

    0.91%

    Downside

    Day's Volatility :2.68%

    Upside

    1.79%

    downward going graph
  • $0.84
    $2.41
    $1.10
    downward going graph

    23.63%

    Downside

    52 Weeks Volatility :65.14%

    Upside

    54.36%

    downward going graph

Returns

PeriodALIGOS THERAPEUTICS INCSector (Health Care)Index (Russel 2000)
3 Months
-23.29%
0.3%
-6.7%
6 Months
12.0%
-8.3%
-6.2%
1 Year
-13.18%
-4.8%
-6.3%
3 Years
-92.46%
23.8%
26.9%

Highlights

Market Capitalization
47.7M
Book Value
$1.97
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-1.99
Wall Street Target Price
4.0
Profit Margin
0.0%
Operating Margin TTM
-611.29%
Return On Assets TTM
-32.34%
Return On Equity TTM
-70.18%
Revenue TTM
14.1M
Revenue Per Share TTM
0.33
Quarterly Revenue Growth YOY
5.8999999999999995%
Gross Profit TTM
-71.2M
EBITDA
-83.9M
Diluted Eps TTM
-1.99
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.82
EPS Estimate Next Year
-1.15
EPS Estimate Current Quarter
-0.48
EPS Estimate Next Quarter
-0.45

Analyst Recommendation

Buy
    77%Buy
    22%Hold
    0
    0%Sell
Based on 9 Wall street analysts offering stock ratings for ALIGOS THERAPEUTICS INC(by analysts ranked 0 to 5 stars)
Based on 9 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
7
7
7
Hold
2
2
4
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 263.64%

Current $1.10
Target $4.00

Technicals Summary

Sell

Neutral

Buy

ALIGOS THERAPEUTICS INC is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
ALIGOS THERAPEUTICS INC
ALIGOS THERAPEUTICS INC
-11.81%
12.0%
-13.18%
-92.46%
-92.46%
Moderna, Inc.
Moderna, Inc.
-5.37%
-28.24%
-13.14%
103.02%
578.71%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-10.12%
-3.55%
9.07%
20.95%
140.97%
Seagen, Inc.
Seagen, Inc.
-2.85%
59.4%
42.61%
21.68%
240.77%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-4.35%
4.3%
22.83%
15.12%
110.67%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
ALIGOS THERAPEUTICS INC
ALIGOS THERAPEUTICS INC
NA
NA
NA
-1.82
-0.7
-0.32
0.0
1.97
Moderna, Inc.
Moderna, Inc.
11.22
11.22
0.0
-1.83
0.27
0.12
0.0
49.12
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
19.72
19.72
9.01
41.59
0.19
0.1
0.0
219.38
Seagen, Inc.
Seagen, Inc.
NA
NA
18.53
-2.88
-0.23
-0.12
0.0
14.54
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
26.53
26.53
0.41
13.64
0.26
0.17
0.0
56.05
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
ALIGOS THERAPEUTICS INC
ALIGOS THERAPEUTICS INC
Buy
$47.7M
-92.46%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$48.1B
578.71%
11.22
31.77%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$79.5B
140.97%
19.72
33.81%
Seagen, Inc.
Seagen, Inc.
Hold
$36.3B
240.77%
NA
-31.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$85.0B
110.67%
26.53
35.4%

Institutional Holdings

  • EcoR1 Capital, LLC

    9.20%
  • Vivo Capital, LLC

    8.26%
  • TANG CAPITAL MANAGEMENT LLC

    7.98%
  • Versant Venture Management LLC

    5.40%
  • Hillhouse Capital Advisors, Ltd.

    5.38%
  • Baker Bros Advisors LP

    4.84%

Corporate Announcements

  • ALIGOS THERAPEUTICS INC Earnings

    ALIGOS THERAPEUTICS INC’s price-to-earnings ratio stands at None

    Read More

Company Information

Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of viral infections and liver diseases. Aligos is focused on the discovery and development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH). Aligos’ strategy is to harness the deep expertise and decades of drug development experience its team has in liver disease, particularly viral hepatitis, to rapidly advance its pipeline of potentially best-in-class molecules.

Organization
ALIGOS THERAPEUTICS INC
Employees
69
CEO
Dr. Lawrence M. Blatt MBA, Ph.D.
Industry
Health Technology

FAQs